| Literature DB >> 34775549 |
Yooksil Sin1, Yuki Yoshimatsu1, Rei Noguchi1, Ryuto Tsuchiya1,2, Takuya Ono1, Taro Akiyama1,2, Fumihiko Nakatani3, Jun Sugaya3, Akihiko Yoshida4, Akira Kawai3, Tadashi Kondo5.
Abstract
Malignant peripheral nerve sheath tumors (MPNSTs) are a rare subtype of mesenchymal tumors that arise from the sheath of peripheral nerves. MPNSTs exhibit strong metastatic potential, leading to poor clinical outcomes. The clinical utility of radiation therapy and chemotherapy is marginal with respect to overall survival and effective systematic therapies for MPNSTs are still needed to improve patient outcome. Although patient-derived cell lines are an essential tool for the development of novel therapies, only a limited number of cell lines have been reported and are available from cell banks. Thus, we established the novel MPNST cell line, NCC-MPNST6-C1, using surgically resected MPNST tissue. The NCC-MPNST6-C1 cells retained copy-number alterations similar to those of the original tumors and demonstrated constant proliferation, spheroid formation, and invasion capability in vitro, which reflected the malignant features of the original tumor tissue. While the NCC-MPNST6-C1 cells did not exhibit tumorigenesis in nude mice, their use in drug screening resulted in anti-cancer agents with low IC50 values. Hence, we conclude that the NCC-MPNST6-C1 cell line is a useful resource for the study of MPNSTs.Entities:
Keywords: Anti-cancer agents; Malignant peripheral nerve sheath tumors; Patient-derived cancer model; Patient-derived cell line; Sarcoma
Mesh:
Substances:
Year: 2021 PMID: 34775549 DOI: 10.1007/s13577-021-00643-8
Source DB: PubMed Journal: Hum Cell ISSN: 0914-7470 Impact factor: 4.174